RXRX — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-08-05

• Genentech Advances First Neuroscience Target into Early Discovery Program

• Genentech has exercised the first Validated Target Option under the companies' neuroscience collaboration, advancing a previously unexplored neuroscience target into a small molecule early discovery program.

• The milestone provides additional early evidence that Recursion's AI-native platform can both discover and play a key role experimentally validating novel therapeutic targets in neuroscience, one of medicine's most challenging therapeutic areas, where decades of research have largely focused on a li…

• In partnership with Roche and Genentech, Recursion built the first whole-genome CRISPR knockout map generated from a subset of over 1 trillion internally manufactured iPSC-derived neuronal cells. Predictions generated from the Maps were experimentally evaluated through a rigorous validation process …

• Next steps will include advancing the target through small molecule design, hit generation and validation using Recursion's AI-native chemistry platform. More broadly, the neuronal and microglial maps of biology remain reusable assets capable of being utilized with biological, genetics, and computat…

Text removed vs the prior filing · source: 10-Q · 2026-05-06

• Preliminary safety and pharmacokinetic (PK) data from REC-1245, a potential first-in-class RBM39 degrader discovered and developed using Recursion’s platform, highlight early clinical progress for a novel approach to targeting cancer vulnerabilities linked to replication stress and DNA repair.

• REC-1245 advanced from biological discovery to development candidate in 18 months, more than twice as fast as the industry average, demonstrating Recursion’s ability to identify novel targets and design differentiated molecules using its integrated AI-enabled platform.

• •REC-1245 was well-tolerated across select solid tumors (n=16)

• •No dose-limiting toxicities (DLTs) have been observed to date, and the maximum tolerated dose has not yet been reached

• •The majority of TRAEs were Grade 1 or 2, most common GI-related events were constipation, nausea, and vomiting

Text added vs the prior filing · source: 10-Q · 2026-08-05

• •We have designed and implemented certain information technology general controls.

• For the three months ended June 30, 2026, management was in the process of integrating the internal controls of the acquired business (Exscientia) into Recursion's existing operations as part of planned integration activities. There were no other changes in internal control over financial reporting …

Text removed vs the prior filing · source: 10-Q · 2026-05-06

• •We have designed and implemented certain information technology general controls and are in the process of implementing additional information technology general controls within the Exscientia business, including controls over the maintenance of appropriate segregation of duties, controls over chan…

• For the three months ended March 31, 2026, management implemented new ERP and P2P systems, replacing legacy systems that had supported a significant portion of our transaction origination, processing and recording. We updated our internal control over financial reporting to accommodate related chang…

• Additionally, management is in the process of integrating the internal controls of the acquired business (Exscientia) into Recursion's existing operations as part of planned integration activities. There were no other changes in internal control over financial reporting (as defined in Rules 13a-15(f…

Text added vs the prior filing · source: 10-Q · 2026-08-05

• On July 31, 2026, Recursion entered into an Eleventh Amendment to the Office Lease by and between Vestar Gateway, LLC (“Vestar”) and Recursion (the "Eleventh Amendment"), extending the term of the Lease as to the Premises for six years, from June 01, 2028 through May 31, 2034. In connection with the…

Text removed vs the prior filing · source: 10-Q · 2026-05-06

• On March 3, 2026, Namandjé Bumpus, a member of our Board of Directors, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the potential sale of up to 12,735 shares of the Company’s Class A common stock until June 2, 2027.